Importance While effective in preventing stroke in patients with atrial fibrillation (AF), warfarin
is limited by a narrow therapeutic profile, a need for lifelong coagulation monitoring, and …

Abstract Aims The PROTECT-AF (WATCHMAN Left Atrial Appendage System for Embolic
Protection in Patients with Atrial Fibrillation) trial found left atrial appendage (LAA) closure …

Background: The risk-benefit ratio of left atrial appendage closure (LAAC) versus systemic
therapy (warfarin) for prevention of stroke, systemic embolism, and cardiovascular death in …

Background In patients with non-valvular atrial fibrillation, embolic stroke is thought to be
associated with left atrial appendage (LAA) thrombi. We assessed the efficacy and safety of …

Abstract Background: The PROTECT AF (WATCHMAN Left Atrial Appendage System for
Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that left atrial …

Background: Left atrial appendage closure (LAAC) was approved by the US Food and Drug
Administration (FDA) as a stroke prevention alternative to warfarin for patients with …

Abstract Background: In the PROTECT AF (Watchman Left Atrial Appendage Closure
Technology for Embolic Protection in Patients With Atrial Fibrillation) trial that evaluated …

Abstract Background The PRAGUE-17 (Left Atrial Appendage Closure vs Novel
Anticoagulation Agents in Atrial Fibrillation) trial demonstrated that left atrial appendage …

Background—The multicenter PROTECT AF study (Watchman Left Atrial Appendage
System for Embolic Protection in Patients With Atrial Fibrillation) was conducted to determine …

Objectives: The purpose of this study was to compare the relative risk of major bleeding with
left atrial appendage (LAA) closure compared with long-term warfarin therapy. Background …